高级检索
当前位置: 首页 > 详情页

Expression and Prognostic Significance of Ferroptosis-related Proteins SLC7A11 and GPX4 in Renal Cell Carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China. [2]Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
出处:
ISSN:

关键词: Renal cell carcinoma ferroptosis SLC7A11 GPX4 prognosis

摘要:
The ferroptosis inhibitory gene solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) inhibit ferroptosis in carcinoma cells. However, whether SLC7A11 and GPX4 serve as an oncogene in renal cell carcinoma (RCC) remains unclear.Immunohistochemistry (IHC) assays were performed to assess the expression of SLC7A11 and GPX4 in human RCC tissues. Clinical-pathological analysis was performed to explore the correlation between SLC7A11 and GPX4 expression. Kaplan-Meier survival analysis was performed to characterise the associations between protein expression and patient progressionfree survival (PFS).The upregulation of SLC7A11 and GPX4 was detected by IHC in RCC tissues compared with that in normal renal tissues. Meanwhile, the expression level of SLC7A11 and GPX4 was correlated with tumour diameter and distant metastasis (P<0.05). Kaplan-Meier survival analysis indicated that patients with high SLC7A11 and GPX4 expression levels exhibited worse PFS than those with low SLC7A11 and GPX4 expression levels (P<0.05).The upregulation of SLC7A11 and GPX4 expression was associated with poor prognosis in patients with RCC. SLC7A11 and GPX4 may serve as diagnostic and prognostic biomarkers for patients with RCC.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学
JCR分区:
出版当年[2023]版:
Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2024]版:
Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
通讯作者:
通讯机构: [2]Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China. [*1]Department of NuclearMedicine, The Fourth Hospital of Hebei Medical University, NO. 12 JianKang Road, Shijiazhuang, Hebei Province, 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号